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Introduction
There has been a remarkable increase in knowledge in the
area of osteoporosis during the last 25 years. Patients
with established osteoporosis have lost more than 50% of
bone mass at critical sites in the skeleton, with marked
disruption of trabecular bone microarchitecture. Anabolic
therapies, therefore, are desperately needed.
Current drugs to treat osteoporosis include bisphospho-
nates, calcitonin, estrogen and related compounds,
vitamin D analogues and ipriflavone. These are all bone
resorption inhibitors, which act mainly to stabilize bone
mass by inhibiting the activity of osteoclasts (the cells
responsible for bone loss). The ability of these drugs to
increase bone mass is relatively small, certainly no more
than 2% per year. It is desirable, therefore, to have a satis-
factory and universally acceptable drug that would stimu-
late new bone formation and correct the disturbance of
trabecular microarchitecture, which is a characteristic of
established osteoporosis.
Chemical nature of statins
Statins are specific, competitive inhibitors of the 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase enzyme. These include naturally occurring lovastatin,
chemically modified simvastatin and pravastatin [1–3] and
the synthetically derived atorvastatin, fluvastatin and
cerivastatin. All of these agents are widely used for lower-
ing cholesterol, and they provide an important and effec-
tive approach to the treatment of hyperlipidemia and
arteriosclerosis [4].
Because the primary site of cholesterol synthesis is the
liver, these agents have been designed to be hepatoselec-
tive. The enzyme HMG-CoA reductase catalyzes the rate-
limiting step in cholesterol biosynthesis, and while
cholesterol is the bulk product of the pathway controlled
by this enzyme, its direct product, mevalonate, is a precur-
sor to a number of non-sterol compounds that are vital to a
variety of cellular functions.
Bone metabolism
Bone is a metabolically active organ in which the organiza-
tional pattern of the mineral and organic components
determines the successful mechanical function of the
skeleton [5,6]. Bone turnover is controlled by defined
agents and mechanisms that regulate bone formation and
bone resorption, which are the two major processes of
bone remodeling. Disturbances in these mechanisms can
lead to either bone loss, resulting in osteoporosis, or an
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Abstract
Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme have recently been shown
to stimulate bone formation in rodents both in vitro and in vivo. In bone cells, these inhibitors increase
the gene expression of bone morphogenetic protein-2, which is an autocrine–paracrine factor for
osteoblast differentiation.
The findings that statins increase bone formation and bone mass in rodents suggest a potential new
action for these compounds, which may be beneficial in patients with established osteoporosis where
marked bone loss has occurred. Recent clinical data suggest that they may reduce the risk of fracture
in patients taking these drugs.
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overgrowth of bone, leading to osteosclerosis. Since new
bone formation is primarily a function of the osteoblast,
agents regulating bone formation can act by either
increasing/decreasing the replication of cells of the
osteoblastic lineage or modifying the differentiated func-
tion of the osteoblast.
It would, therefore, be beneficial to stimulate the
osteoblastic activity at local sites in bone by an oral ana-
bolic agent, resulting in bone formation where needed.
Discovery of the effects of statins on bone
In attempts to identify small molecular weight bone ana-
bolic compounds, attention has focused on the growth
regulatory factors responsible for the control of normal
bone remodeling. The bone morphogenetic proteins
(BMPs) have bone-forming activity and account for the
major proportion of the osteoinductive potential of bone
extracts [7–9]. The BMP-2 promoter has been character-
ized, and based on the properties of BMP-2, this promoter
was utilized as a target to identify new compounds that
stimulate its transcription and subsequent osteoblast dif-
ferentiation.
Identification of small molecules that enhance BMP-2 tran-
scription utilized a cell-based screening assay [10].
Screening a collection of natural products led to the iden-
tification of an extract, containing lovastatin as the active
constituent, that specifically stimulated the BMP-2 pro-
moter. Further investigations found that statins stimulate
bone formation both in vitro and in vivo in animal models
of osteoporosis associated with increased expression of
the BMP-2 gene in bone cells [11].
In vitro effects
Simvastatin, mevastatin and atorvastatin (but not pravas-
tatin) were found to have identical effects to those seen
with lovastatin. Cerivastatin, however, was 10–100-fold
more potent than the other statins. These agents stimu-
lated BMP-2 transcription and also increased endogenous
BMP-2 mRNA and protein expression in human MG63
osteoblastic cells two-fold. These findings have been con-
firmed by other groups [12,13].
It has been shown that statins cause a marked increase in
osteoblast accumulation and new bone formation in cul-
tures of neonatal murine calvaria (Fig. 1). Transient expo-
sure of bone cultures to statins was enough to initiate a
cascade of bone formation, probably induced by the local
production of the osteogenic protein BMP-2. Interestingly,
pravastatin was unable to stimulate the BMP-2 promoter
activity and it did not stimulate new bone formation in
neonatal murine calvaria.
In vivo effects
Initial in vivo experiments have shown that statins injected
locally over the calvaria of normal mice result in a 30–50%
increase in calvarial width. This indicates that statins have
a direct effect on bone formation when applied locally.
There is a requirement, however, for an oral bone anabolic
agent that stimulates systemic new bone formation for the
treatment of bone loss diseases, such as osteoporosis.
Ovariectomized rats, treated systemically with statins,
showed marked increases in bone density when com-
pared to untreated rats. Bones of rats treated orally with
cerivastatin showed a 43% increase in tibial trabecular
volumes, and rats treated orally with simvastatin showed a
38% increase in tibial trabecular volumes compared to the
controls (Fig. 2). Fibroblast growth factor has been previ-
ously shown to stimulate bone formation in vivo and was
used as a positive control. The anabolic effect of statins
was confirmed with significant increases in both bone for-
mation rate and mineral apposition rate in the tibiae of rats
treated with cerivastatin at 0.1 mg/kg/day. Statins, there-
fore, have the potential to stimulate bone formation both in
vitro and  in vivo in rats. Cerivastatin improved cortical
bone strength in ovariectomized rats when used in doses
as low as 0.1 mg/kg/day, and it significantly increased
bone mineral density, bone formation rate, osteocalcin
mRNA levels as well as resistance to fracture [14]. Further
studies have shown that simvastatin given orally to rats
significantly increased cancellous bone compressive
strength in the vertebral bodies of these rats [15].
Mechanism of action
The reduction in mevalonate pathway intermediates with a
subsequent inhibition of prenylation by statins is responsi-
ble for a large proportion of the pleiotropic effects of these
drugs. Mevalonate, farnesyl pyrophosphate and geranyl-
Figure 1
Cultures of murine neonatal calvaria incubated for either 4 or 7 days in
the presence of simvastatin at 1 µM. Small amounts of new bone are
present in control cultures whereas cultures exposed to simvastatin for
4 days show marked new bone formation and osteoblast
accumulation. Cultures exposed for 7 days show further enhancement
of bone formation.239
geranyl pyrophosphate all inhibited statin-stimulated bone
formation. Furthermore, because geranylgeranyl pyrophos-
phate inhibited statin stimulated bone formation, inhibition
of prenylation due to geranylgeranylation must play a
major role in the stimulation of bone formation by this drug.
There are many proteins known to require this form of
prenylation for their activity, including guanosine triphos-
phatases such as Rho, Rac and Rap. These proteins play
important roles in cellular proliferation and differentiation,
and, therefore, any perturbation of their activity influences
cellular activity. A number of the pleiotropic effects of
statins result from their effects on prenylation. One of the
particular roles prenylation plays in cellular activity is its
control of endothelial nitric oxide synthase [16–18] and it
has subsequently been shown to play a major role in the
effects of statins on bone formation.
Clinical findings
Statins are bone anabolic agents, which have been orally
administered to rats, and which have relatively low toxicity
in humans. They could provide an important treatment for
osteoporosis, particularly when significant amounts of tra-
becular bone have been lost. Current therapies for the
treatment of osteoporosis, including estrogen replacement
therapy, selective estrogen receptor modulators, and bis-
phosphonates, are primarily based on blunting the resorp-
tion component of bone remodeling.
Of course, the major question that arises is whether
statins will have similar effects on human bone. Based on
previous findings [13], Bauer and Cummings examined
their large databases to determine if there was any previ-
ously unrecognized association between statin usage and
skeletal status. They found that there was a possible rela-
tionship between statin use, bone mineral density and
subsequent fractures [19]. Since then a study in post-
menopausal women has been published that indicated a
significant increase in bone mineral density associated
with taking statins [20]. Statins have also been shown to
exhibit a protective effect against non-pathological fracture
among older women [21–25]. Conversely, several prelimi-
nary reports (one using the same database as a positive
published report) have suggested that statins do not show
these effects [26–28]. There are major issues with all of
these studies: they are retrospective; the compliance of
patients taking is statins unknown; and the dose of statin
used varied considerably.
All of the statins that are currently available have been
selected for their capacity to target the liver and decrease
cholesterol biosynthesis, but they are poorly distributed to
bone. It is uncertain, therefore, that oral administration of
currently available statins will have beneficial effects on
bone in humans; however, there are several possibilities
for improving biodistribution to bone.
The more recent potent statins such as cerivastatin or
atorvastatin may get past the liver and reach the bone.
Alternative modes of administration of the statins, such as
topical application through a skin patch, may improve
biodistribution. Furthermore, there may be other drugs of
this class that have not been selected for development as
cholesterol-lowering agents because of their relatively
greater biodistribution to peripheral tissues. These may be
ideal drugs for use as bone-active agents.
Conclusion
Perhaps the most important consequence of these find-
ings is not that the statins themselves may be effective
drugs for diseases of bone loss, but rather that these
results focus attention on the pathway of cholesterol
biosynthesis and its relationship to BMP-2 expression and
bone formation. This has been further emphasized by
recent observations that the nitrogen-containing bisphos-
phonates (drugs that reduce bone resorption and have a
large market for osteoporosis) also target enzymes in this
pathway. This may lead to the identification of other poten-
tial molecular targets for drug discovery as well as other
therapeutic approaches to enhance bone formation, and
thus produce the ideal anabolic agent for osteoporosis.
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